GSK update on Bexxar
"My own guess is that probably we will have an advisory committee" to review the non-Hodgkin's lymphoma therapy Bexxar (iodine I 131 tositumomab) once Corixa has responded to FDA's March "complete review" letter for the product, GlaxoSmithKline VP-New Product Development James Palmer tells Goldman Sachs healthcare conference June 13. "We are working closely with Corixa, dealing with the questions. That is going very well, and we would expect to probably get to the next stage in the second half of this year. There will have to be a decision about whether there is an advisory committee or not. It is speculative right now"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth